Dana C Miskulin1, Daniel E Weiner2, Hocine Tighiouart3, Eduardo K Lacson2,4, Klemens B Meyer2, Taimur Dad2, Harold J Manley4. 1. Division of Nephrology, Tufts Medical Center and Dmiskulin@tuftsmedicalcenter.org. 2. Division of Nephrology, Tufts Medical Center and. 3. Biostatistics, Epidemiology, and Research Design Center, Tufts University School of Medicine, Boston, Massachusetts; and. 4. Dialysis Clinic Inc., Nashville, Tennessee.
Abstract
BACKGROUND AND OBJECTIVES: High-dose influenza vaccine, which contains fourfold more antigen than standard dose, is associated with fewer cases of influenza and less influenza-related morbidity in the elderly general population. Whether the high-dose influenza vaccine benefits patients on dialysis, whose immune response to vaccination is less robust than that of healthy patients, is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We compared hospitalizations and deaths during the 2015-2016 and 2016-2017 influenza seasons by vaccine type (standard trivalent, standard quadrivalent, and high-dose trivalent influenza vaccine) administered within a national dialysis organization. The association of vaccine type with outcomes was estimated using Cox proportional hazards regression with adjustment for patient factors and "center effect." Analyses were stratified by age and dialysis modality. RESULTS: Between September 1 and December 31, 2015, standard dose trivalent, standard dose quadrivalent, and high-dose trivalent influenza vaccines were administered to 3057 (31%), 5981 (61%), and 805 (8%) patients, respectively. The adjusted rates of first hospitalizations by vaccine type during the influenza season were 8.43, 7.88, and 7.99 per 100 patient-months, respectively, and the adjusted rates of death were 1.00, 0.97, and 1.04, respectively. These differences were not significant. In 2016, 3614 (39%) received quadrivalent vaccine, and 5700 (61%) received high-dose trivalent vaccine. The adjusted rates of first hospitalization by vaccine type were 8.71 and 8.04 per 100 patient-months, respectively, and the adjusted rates of death were 0.98 and 1.02, respectively. Receipt of high dose was associated with a significant reduction in hospitalization (hazard ratio, 0.93; 95% confidence interval, 0.86 to 1.00; P=0.04); there was no significant association with death. There was no significant heterogeneity of either association by age group or dialysis modality. CONCLUSIONS: Receipt of high-dose compared with standard dose influenza vaccine in 2016-2017 was associated with lower rates of hospitalization in patients on dialysis, although that was not seen in 2015-2016.
BACKGROUND AND OBJECTIVES: High-dose influenza vaccine, which contains fourfold more antigen than standard dose, is associated with fewer cases of influenza and less influenza-related morbidity in the elderly general population. Whether the high-dose influenza vaccine benefits patients on dialysis, whose immune response to vaccination is less robust than that of healthy patients, is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We compared hospitalizations and deaths during the 2015-2016 and 2016-2017 influenza seasons by vaccine type (standard trivalent, standard quadrivalent, and high-dose trivalent influenza vaccine) administered within a national dialysis organization. The association of vaccine type with outcomes was estimated using Cox proportional hazards regression with adjustment for patient factors and "center effect." Analyses were stratified by age and dialysis modality. RESULTS: Between September 1 and December 31, 2015, standard dose trivalent, standard dose quadrivalent, and high-dose trivalent influenza vaccines were administered to 3057 (31%), 5981 (61%), and 805 (8%) patients, respectively. The adjusted rates of first hospitalizations by vaccine type during the influenza season were 8.43, 7.88, and 7.99 per 100 patient-months, respectively, and the adjusted rates of death were 1.00, 0.97, and 1.04, respectively. These differences were not significant. In 2016, 3614 (39%) received quadrivalent vaccine, and 5700 (61%) received high-dose trivalent vaccine. The adjusted rates of first hospitalization by vaccine type were 8.71 and 8.04 per 100 patient-months, respectively, and the adjusted rates of death were 0.98 and 1.02, respectively. Receipt of high dose was associated with a significant reduction in hospitalization (hazard ratio, 0.93; 95% confidence interval, 0.86 to 1.00; P=0.04); there was no significant association with death. There was no significant heterogeneity of either association by age group or dialysis modality. CONCLUSIONS: Receipt of high-dose compared with standard dose influenza vaccine in 2016-2017 was associated with lower rates of hospitalization in patients on dialysis, although that was not seen in 2015-2016.
Authors: Nilufer E Broeders; Anneleen Hombrouck; Anne Lemy; Karl Martin Wissing; Judith Racapé; Karine Gastaldello; Annick Massart; Steven Van Gucht; Laura Weichselbaum; Aurelie De Mul; Bernard Brochier; Isabelle Thomas; Daniel Abramowicz Journal: Clin J Am Soc Nephrol Date: 2011-09-15 Impact factor: 8.237
Authors: Leah J McGrath; Abhijit V Kshirsagar; Stephen R Cole; Lily Wang; David J Weber; Til Stürmer; M Alan Brookhart Journal: Arch Intern Med Date: 2012-04-09
Authors: Undine Ott; Andreas Sauerbrei; Jeannette Lange; Anna Schäfler; Mario Walther; Gunter Wolf; Peter Wutzler; Roland Zell; Andi Krumbholz Journal: Med Microbiol Immunol Date: 2012-02-17 Impact factor: 3.402
Authors: Hector S Izurieta; Nicole Thadani; David K Shay; Yun Lu; Aaron Maurer; Ivo M Foppa; Riley Franks; Douglas Pratt; Richard A Forshee; Thomas MaCurdy; Chris Worrall; Andrew E Howery; Jeffrey Kelman Journal: Lancet Infect Dis Date: 2015-02-09 Impact factor: 25.071
Authors: Carlos A DiazGranados; Corwin A Robertson; H Keipp Talbot; Victoria Landolfi; Andrew J Dunning; David P Greenberg Journal: Vaccine Date: 2015-07-26 Impact factor: 3.641
Authors: Nathaniel D Lambert; Inna G Ovsyannikova; V Shane Pankratz; Robert M Jacobson; Gregory A Poland Journal: Expert Rev Vaccines Date: 2012-08 Impact factor: 5.217
Authors: Lisa A Grohskopf; Leslie Z Sokolow; Karen R Broder; Emmanuel B Walter; Alicia M Fry; Daniel B Jernigan Journal: MMWR Recomm Rep Date: 2018-08-24
Authors: J Bradley Layton; Leah J McGrath; John M Sahrmann; Yinjiao Ma; Vikas R Dharnidharka; Caroline O'Neil; David J Weber; Anne M Butler Journal: Vaccine Date: 2020-06-19 Impact factor: 3.641
Authors: Anne M Butler; J Bradley Layton; Vikas R Dharnidharka; John M Sahrmann; Marissa J Seamans; David J Weber; Leah J McGrath Journal: Am J Kidney Dis Date: 2019-08-01 Impact factor: 8.860
Authors: Michael Jahn; Johannes Korth; Oliver Dorsch; Olympia Evdoxia Anastasiou; Adalbert Krawczyk; Leonie Brochhagen; Lukas van de Sand; Burkhard Sorge-Hädicke; Bartosz Tyczynski; Oliver Witzke; Ulf Dittmer; Sebastian Dolff; Benjamin Wilde; Andreas Kribben Journal: Vaccines (Basel) Date: 2022-02-18